4.7 Article

Suppressed insulin signaling and increased apoptosis in Cd38-null islets

Journal

DIABETES
Volume 55, Issue 10, Pages 2737-2746

Publisher

AMER DIABETES ASSOC
DOI: 10.2337/db05-1455

Keywords

-

Funding

  1. NIAID NIH HHS [AI-057996] Funding Source: Medline
  2. NIDDK NIH HHS [DK-31842, R01 DK073716] Funding Source: Medline

Ask authors/readers for more resources

CD38 is a multifunctional enzyme capable of generating metabolites that release Ca2+ from intracellular stores, including nicotinic acid adenine dinucleotide phosphate (NAADP). A number of studies have led to the controversial proposal that CD38 mediates an alternate pathway for glucose-stimulated insulin release and contributes to the pathogenesis of diabetes. It has recently been shown that NAADP mediates Ca2+ mobilization by insulin in human pancreatic beta-cells. In the present study, we report altered Ca2+ homeostasis and reduced responsiveness to insulin, but not glucose, in Cd38(-/-) beta-cells. In keeping with the antiapoptotic role of insulin signaling, Cd38(-/-) islets were significantly more susceptible to apoptosis compared with islets isolated from littermate controls. This finding correlated with disrupted islet architecture and reduced beta-cell mass in Cd38(-/-) mice, both in the context of a normal lab diet and a high-fat diet. Nevertheless, we did not find robust differences in glucose homeostasis in vivo or glucose signaling in vitro in Cd38(-/-) mice on the C57BL/6 genetic background, in contrast to previous studies by others of Cd38 knockout mice on the ICR background. Thus, our results suggest that CD38 plays a role in novel antiapoptotic signaling pathways but does not directly control glucose signaling in pancreatic beta-cells.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available